ASCO Annual Meeting
ASCO Annual Meeting
July 15, 2017
3 min watch
Save

VIDEO: LATITUDE, STAMPEDE trials provide ‘practice-changing’ findings in prostate cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The results of the LATITUDE and STAMPEDE trials presented at the ASCO Annual Meeting position abiraterone acetate “as the new frontline agent for men with castration-naive, metastatic prostate cancer,” according to Jorge Garcia, MD, of the Cleveland Clinic.

Garcia discusses the similarities between the trials and how abiraterone acetate (Zytiga, Janssen) fits into the treatment landscape for this disease. There are still unanswered questions, including issues related to cost and length of therapy, but the trials have one thing in common, according to Garcia.

“If you start men on androgen deprivation therapy and add abiraterone acetate and prednisone out front, there is a significant improvement in survival compared with androgen deprivation therapy alone,” he told HemOnc Today.